| 09/01 | Morphosys Ag : MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofib.. | EQ |
| 05/01 | MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financ.. | EQ |
| 05/01 | Ad Hoc : MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 20.. | EQ |
| 2022 | InnoCare Announces Approval of Tafasitamab in Combination with Lenalidomide for the Tre.. | AQ |
| 2022 | Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023 | AQ |
| 2022 | Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023 | EQ |
| 2022 | MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Incl.. | EQ |
| 2022 | MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from F.. | EQ |
| 2022 | MorphoSys Out Licenses Pre-Clinical Oncology Program | AQ |
| 2022 | MorphoSys Out Licenses Pre-Clinical Oncology Program | EQ |
| 2022 | Afr : MorphoSys AG: Preliminary announcement of the publication of quarterly reports and q.. | EQ |
| 2022 | Morphosys Ag : Financial Calendar 2023 | EQ |
| 2022 | Morphosys : Notification of managers`transactions according to article 19 MAR - Form 6-K | PU |
| 2022 | Dd : MorphoSys AG: Krisja Vermeylen, buy | EQ |
| 2022 | Morphosys : Notification of managers`transactions according to article 19 MAR - Form 6-K | PU |
| 2022 | Dd : MorphoSys AG: Dr. Marc Cluzel, buy | EQ |
| 2022 | MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results | EQ |
| 2022 | MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results | BU |
| 2022 | MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gant.. | AQ |
| 2022 | MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gant.. | EQ |
| 2022 | Ad Hoc : MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program fo.. | EQ |
| 2022 | Invitation to MorphoSys Third Quarter and First Nine Months 2022 Results Conference Cal.. | AQ |
| 2022 | Invitation to MorphoSys' Third Quarter and First Nine Months 2022 Results Conference Ca.. | EQ |
| 2022 | MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Present.. | EQ |
| 2022 | MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat Supporting.. | AQ |
| 2022 | GSK, MorphoSys Licensing Partner, Provides Update on ContRAst Phase III Program for Oti.. | AQ |
| 2022 | MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209).. | EQ |
| 2022 | GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Ot.. | EQ |
| 2022 | MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance.. | AQ |
| 2022 | MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance.. | EQ |
| 2022 | Ad Hoc : MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial.. | EQ |
| 2022 | MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatm.. | AQ |
| 2022 | MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatm.. | AQ |
| 2022 | MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatm.. | EQ |
| 2022 | InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab .. | AQ |
| 2022 | MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following .. | AQ |
| 2022 | MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following .. | EQ |
| 2022 | Morphosys : Reports Second Quarter and First Half 2022 Financial Results - Form 6-K | PU |
| 2022 | MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results | EQ |
| 2022 | MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results | BU |
| 2022 | Morphosys : Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Confe.. | PU |
| 2022 | Morphosys Ag : Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Co.. | EQ |
| 2022 | MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guida.. | AQ |
| 2022 | MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance.. | AQ |
| 2022 | Ad Hoc : MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial.. | PU |
| 2022 | MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance.. | EQ |
| 2022 | Ad Hoc : MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial.. | EQ |
| 2022 | Morphosys Group : First Quarter Interim Statement January – March 2022 - Form 6-K | PU |
| 2022 | MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzarta.. | EQ |
| 2022 | MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzarta.. | BU |
| 2022 | Morphosys : Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monju.. | PU |
| 2022 | Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafa.. | EQ |
| 2022 | Morphosys : Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Pot.. | PU |
| 2022 | MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Po.. | EQ |
| 2022 | MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Po.. | BU |
| 2022 | MorphoSys AG Reports Outcome of Annual General Meeting 2022 | AQ |
| 2022 | MorphoSys AG Reports Outcome of Annual General Meeting 2022 | EQ |
| 2022 | MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022.. | EQ |
| 2022 | MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022.. | BU |
| 2022 | MorphoSys AG Reports First Quarter 2022 Financial Results | EQ |
| 2022 | MorphoSys AG Reports First Quarter 2022 Financial Results | BU |
| 2022 | Morphosys : Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call .. | PU |
| 2022 | Morphosys : Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call .. | PU |
| 2022 | Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5,.. | EQ |
| 2022 | Morphosys : Notification of managers`transactions according to article 19 MAR - Form 6-K | PU |
| 2022 | Morphosys Ag : Notification and public disclosure of transactions by persons | EQ |
| 2022 | MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi (tafasitamab) in.. | AQ |
| 2022 | Morphosys : and Incyte Announce Swissmedic Temporary Approval of Minjuvi® (tafasitamab) in.. | PU |
| 2022 | MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab).. | EQ |
| 2022 | Morphosys : Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corpo.. | PU |
| 2022 | Morphosys : ESG Report 2021 | PU |
| 2022 | MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides C.. | BU |
| 2022 | MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides C.. | EQ |
| 2022 | Morphosys : National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (ta.. | PU |
| 2022 | Morphosys : National Comprehensive Cancer Network® Updates Designation of Monjuvi® (tafasi.. | PU |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (België)
Rapport
